Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reiji Yoshimura

Showing results (121-130 of 297) with videos related to

Pageof 30
Sort By:
Human Psychopharmacology|September 23, 2008
Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertralineReiji Yoshimura, Wakako Umene-Nakano, Nobuhisa Ueda, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 12, 2009
Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetineAtsuko Ikenouchi-Sugita, Reiji Yoshimura, Hikaru Hori, et al.
The International Journal of Neuropsychopharmacology|December 19, 2014
Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose methodYoshio Yamanouchi, Tsuruhei Sukegawa, Ataru Inagaki, et al.
Psychiatry Research. Neuroimaging|April 17, 2020
Whole-brain structural covariance network abnormality in first-episode and drug-naïve major depressive disorderKeita Watanabe, Shingo Kakeda, Asuka Katsuki, et al.
International Journal of Molecular Sciences|September 28, 2023
Serum Extracellular Vesicle-Derived hsa-miR-2277-3p and hsa-miR-6813-3p Are Potential Biomarkers for Major Depression: A Preliminary StudyIssei Seki, Hiroto Izumi, Naomichi Okamoto, et al.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|November 4, 2015
[Individually Safe and Realistic Correction of Antipsychotic Polypharmacy and High-dose Regimens in Japanese Patients with Chronic Schizophrenia: The SCAP method]Yoshio Yamanouchi, Tsuruhei Sukegawa, Ataru Inagaki, et al.
Journal of Clinical Psychopharmacology|January 5, 2013
Serum brain-derived neurotrophic factor levels at 6 months after remission are not associated with subsequent depressive episodesReiji Yoshimura, Hikaru Hori, Atsuko Sugita-Ikenouchi, et al.
European Archives of Psychiatry and Clinical Neuroscience|November 22, 2023
Effect modification of tumor necrosis factor-α on the kynurenine and serotonin pathways in major depressive disorder on type 2 diabetes mellitusNaomichi Okamoto, Takashi Hoshikawa, Yuichi Honma, et al.
Human Psychopharmacology|February 15, 2008
Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot studyReiji Yoshimura, Shingo Kakihara, Wakako Umene-Nakano, et al.
Journal of UOEH|March 12, 2013
The effects of a walking intervention on depressive feelings and social adaptation in healthy workersAtsuko Ikenouchi-Sugita, Reiji Yoshimura, Kazunari Sugita, et al.
Pageof 30

Showing results (121-130 of 297) with videos related to

Sort By:
Pageof 30
Human Psychopharmacology|September 23, 2008
Addition of risperidone to sertraline improves sertraline-resistant refractory depression without influencing plasma concentrations of sertraline and desmethylsertralineReiji Yoshimura, Wakako Umene-Nakano, Nobuhisa Ueda, et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 12, 2009
Effects of antidepressants on plasma metabolites of nitric oxide in major depressive disorder: comparison between milnacipran and paroxetineAtsuko Ikenouchi-Sugita, Reiji Yoshimura, Hikaru Hori, et al.
The International Journal of Neuropsychopharmacology|December 19, 2014
Evaluation of the individual safe correction of antipsychotic agent polypharmacy in Japanese patients with chronic schizophrenia: validation of safe corrections for antipsychotic polypharmacy and the high-dose methodYoshio Yamanouchi, Tsuruhei Sukegawa, Ataru Inagaki, et al.
Psychiatry Research. Neuroimaging|April 17, 2020
Whole-brain structural covariance network abnormality in first-episode and drug-naïve major depressive disorderKeita Watanabe, Shingo Kakeda, Asuka Katsuki, et al.
International Journal of Molecular Sciences|September 28, 2023
Serum Extracellular Vesicle-Derived hsa-miR-2277-3p and hsa-miR-6813-3p Are Potential Biomarkers for Major Depression: A Preliminary StudyIssei Seki, Hiroto Izumi, Naomichi Okamoto, et al.
Seishin Shinkeigaku Zasshi = Psychiatria Et Neurologia Japonica|November 4, 2015
[Individually Safe and Realistic Correction of Antipsychotic Polypharmacy and High-dose Regimens in Japanese Patients with Chronic Schizophrenia: The SCAP method]Yoshio Yamanouchi, Tsuruhei Sukegawa, Ataru Inagaki, et al.
Journal of Clinical Psychopharmacology|January 5, 2013
Serum brain-derived neurotrophic factor levels at 6 months after remission are not associated with subsequent depressive episodesReiji Yoshimura, Hikaru Hori, Atsuko Sugita-Ikenouchi, et al.
European Archives of Psychiatry and Clinical Neuroscience|November 22, 2023
Effect modification of tumor necrosis factor-α on the kynurenine and serotonin pathways in major depressive disorder on type 2 diabetes mellitusNaomichi Okamoto, Takashi Hoshikawa, Yuichi Honma, et al.
Human Psychopharmacology|February 15, 2008
Acute risperidone treatment did not increase daily cigarette consumption or plasma levels of cotinine and caffeine: a pilot studyReiji Yoshimura, Shingo Kakihara, Wakako Umene-Nakano, et al.
Journal of UOEH|March 12, 2013
The effects of a walking intervention on depressive feelings and social adaptation in healthy workersAtsuko Ikenouchi-Sugita, Reiji Yoshimura, Kazunari Sugita, et al.
Pageof 30